BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2373919)

  • 1. [A clinical study on multiple tumor markers following therapy in patients with uterine cervical carcinoma].
    Hiura M; Yorishima M; Tanaka M; Yokoyama T; Myoga H; Chiba T; Nakanishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):471-8. PubMed ID: 2373919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
    Geyer H; Schwörer D; Pfleiderer A
    Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of serum levels of SCC antigen in patients with esophageal squamous cell carcinoma].
    Ikeda K; Terashima M; Ishida K; Okamoto K; Suzuki S; Murakami K; Ohtsu T; Suzuki K; Niitsu Y; Obonai H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):677-82. PubMed ID: 3355186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
    Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
    Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
    Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer.
    Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S
    Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
    Ngan HY; Cheng GT; Yeung WS; Wong LC; Ma HK
    Gynecol Oncol; 1994 Jan; 52(1):63-8. PubMed ID: 8307503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma.
    Meier W; Stieber P; Hasholzner U; Baumgartner L; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2959-62. PubMed ID: 9329575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
    Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
    Volgger B; Aspisirengil C; Genser-Krimbacher E; Ciresa-Koenig A; Daxenbichler G; Fuchs D; Windbichler G; Marth C
    Cancer Lett; 2008 Apr; 262(2):183-9. PubMed ID: 18226853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The monitoring of gynecological radiotherapy using serial tumor marker determinations].
    Wagner RK; Atzinger A; Breit A
    Strahlenther Onkol; 1990 Jul; 166(7):446-52. PubMed ID: 2200151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
    J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers.
    Lam CP; Yuan CC; Jeng FS; Tsai LC; Yeh SH; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1992 Jul; 50(1):7-13. PubMed ID: 1326391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.